A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Effects of Intravenous Serelaxin Infusion on Micro- and Macrovascular Function in Patients With Coronary Artery Disease

Trial Profile

A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Effects of Intravenous Serelaxin Infusion on Micro- and Macrovascular Function in Patients With Coronary Artery Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Coronary artery disease
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 23 Sep 2016 Status changed from recruiting to completed.
    • 05 Oct 2015 Planned End Date changed from 1 Jan 2016 to 1 Aug 2016, according to ClinicalTrials.gov record.
    • 05 Oct 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Aug 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top